Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer
Background: Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated their role in breast cancer resistance to anthracycline-based chemotherapy. Materials and Methods: Using real-time reverse transcriptase polymerase chain reaction (RT-PCR) a...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2004-09, Vol.24 (5A), p.2931-2939 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2939 |
|---|---|
| container_issue | 5A |
| container_start_page | 2931 |
| container_title | Anticancer research |
| container_volume | 24 |
| creator | FANEYTE, Ian F KRISTEL, Petra M. P VAN DE VIJVER, Marc J |
| description | Background: Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated
their role in breast cancer resistance to anthracycline-based chemotherapy. Materials and Methods: Using real-time reverse
transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), the expression of MRP1 - 3 was quantified
in nine breast cancer cell lines and 30 breast carcinoma samples. Results: MRP1 - 3 mRNA was detectable in all breast cancer
cell lines and tumor samples. No increase of expression was detected between untreated carcinoma and post-neoadjuvant anthracycline
treatment tumor samples. IHC failed to detect the proteins. MRP1 - 3 expression was not associated with tumor response to
treatment or with outcome. Conclusion: MRP1 - 3 are expressed in breast cancer cells, but are not detected with IHC. We have
found no evidence linking these proteins to clinical drug resistance in a small but well-documented series of breast cancer
samples. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_15517899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15517899</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-a353726ce255aa9b0ec11bb8d0e5fdc2a07cff68cf172a6b38cb778078930bdf3</originalsourceid><addsrcrecordid>eNpFj1tLAzEQhYMotlb_guRFn1zIxSSbx7XUKrRYij4vk8t2I9ttSbZo_71bW_FlZjh8czjnDA2p0jRTgpNzNCRMkEwRIgboKqVPQqTUOb9EAyoEVbnWQ9TMd00XXNyt8NKnkDporcdFShsboPMOT33rE54vF_ThMBmG1h0OjkOLFzGsIe5_taLt6gh2b5vQejz53m5S__4UPaQOjw-28RpdVNAkf3PaI_TxPHkfv2Szt-nruJhlNZN5lwEXXDFpPRMCQBviLaXG5I54UTnLgChbVTK3FVUMpOG5NUrlpG_EiXEVH6Hbo-92Z9beldtjzPKvdg_cnQBIFpoq9vFC-uck1ZJz1nP3R64Oq_orRF-mNTRNb8tLiOyxFEXJNKf8B4LBbog</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>FANEYTE, Ian F ; KRISTEL, Petra M. P ; VAN DE VIJVER, Marc J</creator><creatorcontrib>FANEYTE, Ian F ; KRISTEL, Petra M. P ; VAN DE VIJVER, Marc J</creatorcontrib><description>Background: Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated
their role in breast cancer resistance to anthracycline-based chemotherapy. Materials and Methods: Using real-time reverse
transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), the expression of MRP1 - 3 was quantified
in nine breast cancer cell lines and 30 breast carcinoma samples. Results: MRP1 - 3 mRNA was detectable in all breast cancer
cell lines and tumor samples. No increase of expression was detected between untreated carcinoma and post-neoadjuvant anthracycline
treatment tumor samples. IHC failed to detect the proteins. MRP1 - 3 expression was not associated with tumor response to
treatment or with outcome. Conclusion: MRP1 - 3 are expressed in breast cancer cells, but are not detected with IHC. We have
found no evidence linking these proteins to clinical drug resistance in a small but well-documented series of breast cancer
samples.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 15517899</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Anthracyclines - administration & dosage ; Anthracyclines - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Breast Neoplasms - surgery ; Cell Line, Tumor ; Clinical Trials, Phase II as Topic ; Cyclophosphamide - administration & dosage ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Epirubicin - administration & dosage ; Fluorouracil - administration & dosage ; Gene Expression - drug effects ; Genes, MDR - drug effects ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Mammary gland diseases ; Medical sciences ; Membrane Transport Proteins - biosynthesis ; Membrane Transport Proteins - genetics ; Multidrug Resistance-Associated Proteins - biosynthesis ; Multidrug Resistance-Associated Proteins - genetics ; Multidrug Resistance-Associated Proteins - metabolism ; Neoadjuvant Therapy ; RNA, Messenger - biosynthesis ; RNA, Messenger - genetics ; Tumors</subject><ispartof>Anticancer research, 2004-09, Vol.24 (5A), p.2931-2939</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16196332$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15517899$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FANEYTE, Ian F</creatorcontrib><creatorcontrib>KRISTEL, Petra M. P</creatorcontrib><creatorcontrib>VAN DE VIJVER, Marc J</creatorcontrib><title>Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated
their role in breast cancer resistance to anthracycline-based chemotherapy. Materials and Methods: Using real-time reverse
transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), the expression of MRP1 - 3 was quantified
in nine breast cancer cell lines and 30 breast carcinoma samples. Results: MRP1 - 3 mRNA was detectable in all breast cancer
cell lines and tumor samples. No increase of expression was detected between untreated carcinoma and post-neoadjuvant anthracycline
treatment tumor samples. IHC failed to detect the proteins. MRP1 - 3 expression was not associated with tumor response to
treatment or with outcome. Conclusion: MRP1 - 3 are expressed in breast cancer cells, but are not detected with IHC. We have
found no evidence linking these proteins to clinical drug resistance in a small but well-documented series of breast cancer
samples.</description><subject>Anthracyclines - administration & dosage</subject><subject>Anthracyclines - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - surgery</subject><subject>Cell Line, Tumor</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Drug Resistance, Neoplasm</subject><subject>Epirubicin - administration & dosage</subject><subject>Fluorouracil - administration & dosage</subject><subject>Gene Expression - drug effects</subject><subject>Genes, MDR - drug effects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Membrane Transport Proteins - biosynthesis</subject><subject>Membrane Transport Proteins - genetics</subject><subject>Multidrug Resistance-Associated Proteins - biosynthesis</subject><subject>Multidrug Resistance-Associated Proteins - genetics</subject><subject>Multidrug Resistance-Associated Proteins - metabolism</subject><subject>Neoadjuvant Therapy</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - genetics</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFj1tLAzEQhYMotlb_guRFn1zIxSSbx7XUKrRYij4vk8t2I9ttSbZo_71bW_FlZjh8czjnDA2p0jRTgpNzNCRMkEwRIgboKqVPQqTUOb9EAyoEVbnWQ9TMd00XXNyt8NKnkDporcdFShsboPMOT33rE54vF_ThMBmG1h0OjkOLFzGsIe5_taLt6gh2b5vQejz53m5S__4UPaQOjw-28RpdVNAkf3PaI_TxPHkfv2Szt-nruJhlNZN5lwEXXDFpPRMCQBviLaXG5I54UTnLgChbVTK3FVUMpOG5NUrlpG_EiXEVH6Hbo-92Z9beldtjzPKvdg_cnQBIFpoq9vFC-uck1ZJz1nP3R64Oq_orRF-mNTRNb8tLiOyxFEXJNKf8B4LBbog</recordid><startdate>20040901</startdate><enddate>20040901</enddate><creator>FANEYTE, Ian F</creator><creator>KRISTEL, Petra M. P</creator><creator>VAN DE VIJVER, Marc J</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20040901</creationdate><title>Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer</title><author>FANEYTE, Ian F ; KRISTEL, Petra M. P ; VAN DE VIJVER, Marc J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-a353726ce255aa9b0ec11bb8d0e5fdc2a07cff68cf172a6b38cb778078930bdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anthracyclines - administration & dosage</topic><topic>Anthracyclines - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - surgery</topic><topic>Cell Line, Tumor</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Drug Resistance, Neoplasm</topic><topic>Epirubicin - administration & dosage</topic><topic>Fluorouracil - administration & dosage</topic><topic>Gene Expression - drug effects</topic><topic>Genes, MDR - drug effects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Membrane Transport Proteins - biosynthesis</topic><topic>Membrane Transport Proteins - genetics</topic><topic>Multidrug Resistance-Associated Proteins - biosynthesis</topic><topic>Multidrug Resistance-Associated Proteins - genetics</topic><topic>Multidrug Resistance-Associated Proteins - metabolism</topic><topic>Neoadjuvant Therapy</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FANEYTE, Ian F</creatorcontrib><creatorcontrib>KRISTEL, Petra M. P</creatorcontrib><creatorcontrib>VAN DE VIJVER, Marc J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FANEYTE, Ian F</au><au>KRISTEL, Petra M. P</au><au>VAN DE VIJVER, Marc J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2004-09-01</date><risdate>2004</risdate><volume>24</volume><issue>5A</issue><spage>2931</spage><epage>2939</epage><pages>2931-2939</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated
their role in breast cancer resistance to anthracycline-based chemotherapy. Materials and Methods: Using real-time reverse
transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), the expression of MRP1 - 3 was quantified
in nine breast cancer cell lines and 30 breast carcinoma samples. Results: MRP1 - 3 mRNA was detectable in all breast cancer
cell lines and tumor samples. No increase of expression was detected between untreated carcinoma and post-neoadjuvant anthracycline
treatment tumor samples. IHC failed to detect the proteins. MRP1 - 3 expression was not associated with tumor response to
treatment or with outcome. Conclusion: MRP1 - 3 are expressed in breast cancer cells, but are not detected with IHC. We have
found no evidence linking these proteins to clinical drug resistance in a small but well-documented series of breast cancer
samples.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>15517899</pmid><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2004-09, Vol.24 (5A), p.2931-2939 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_pubmed_primary_15517899 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Anthracyclines - administration & dosage Anthracyclines - pharmacology Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - pharmacology Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - surgery Cell Line, Tumor Clinical Trials, Phase II as Topic Cyclophosphamide - administration & dosage Disease-Free Survival Drug Resistance, Neoplasm Epirubicin - administration & dosage Fluorouracil - administration & dosage Gene Expression - drug effects Genes, MDR - drug effects Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Mammary gland diseases Medical sciences Membrane Transport Proteins - biosynthesis Membrane Transport Proteins - genetics Multidrug Resistance-Associated Proteins - biosynthesis Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - metabolism Neoadjuvant Therapy RNA, Messenger - biosynthesis RNA, Messenger - genetics Tumors |
| title | Multidrug Resistance Associated Genes MRP1, MRP2 and MRP3 in Primary and Anthracycline Exposed Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T00%3A45%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multidrug%20Resistance%20Associated%20Genes%20MRP1,%20MRP2%20and%20MRP3%20in%20Primary%20and%20Anthracycline%20Exposed%20Breast%20Cancer&rft.jtitle=Anticancer%20research&rft.au=FANEYTE,%20Ian%20F&rft.date=2004-09-01&rft.volume=24&rft.issue=5A&rft.spage=2931&rft.epage=2939&rft.pages=2931-2939&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E15517899%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15517899&rfr_iscdi=true |